{"entity":{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","aka":[],"tldr":"SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.","summary":"SSGJ-705 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and HER2. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-HER2 bispecifc antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials. The largest, NCT07022002, plans to enrol 340 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of SSGJ-705","url":"https://clinicaltrials.gov/search?intr=SSGJ-705"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["pd1","her2"],"drugs":[],"companies":["3sbio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07646626","nct07022002"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"Monoclonal antibody directed at PD-1 and HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ssgj-705/","neighbours":{"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/"}],"trial":[{"id":"nct07022002","kind":"trial","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07022002/"},{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/"}]}}